Enliven Therapeutics (NASDAQ:ELVN) Stock Keeps “Buy” Rating at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research note issued to investors on Friday,Benzinga reports. Guggenheim currently has a $78.00 price target on the stock.

A number of other research analysts have also recently commented on the stock. Zacks Research cut shares of Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. Morgan Stanley began coverage on shares of Enliven Therapeutics in a research note on Friday, October 2nd. They set an “overweight” rating and a $70.00 target price for the company. William Blair started coverage on shares of Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating for the company. Stifel Nicolaus boosted their price target on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Thursday, October 15th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $75.44.

Enliven Therapeutics Stock Up 10.4%

NASDAQ:ELVN traded up $4.64 on Friday, reaching $49.43. The company’s stock had a trading volume of 969,641 shares, compared to its average volume of 1,622,008. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $62.32. The firm has a market cap of $3.62 billion, a price-to-earnings ratio of -28.91 and a beta of 0.34. The stock has a 50 day moving average price of $47.25 and a 200 day moving average price of $43.08.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.09. Equities research analysts expect that Enliven Therapeutics will post -1.79 EPS for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other news, Director J. Scott Garland sold 13,000 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total transaction of $606,710.00. Following the sale, the director owned 13,000 shares of the company’s stock, valued at approximately $606,710. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Monday, October 19th. The shares were sold at an average price of $38.48, for a total value of $231,572.64. Following the completion of the sale, the chief financial officer owned 38,000 shares in the company, valued at approximately $1,462,240. The trade was a 13.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 31,054 shares of company stock valued at $1,493,823 in the last three months. 3.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. KBC Group NV purchased a new stake in Enliven Therapeutics during the 1st quarter worth about $38,000. Three Bridge Wealth Advisors LLC purchased a new position in shares of Enliven Therapeutics in the 3rd quarter valued at about $53,000. State of Wyoming acquired a new position in shares of Enliven Therapeutics during the second quarter worth about $96,000. Sterling Capital Management LLC grew its position in shares of Enliven Therapeutics by 1,180.7% during the third quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock worth $88,000 after buying an additional 1,771 shares in the last quarter. Finally, FNY Investment Advisers LLC acquired a new position in shares of Enliven Therapeutics during the second quarter worth about $126,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.